Houston-based Salarius Pharmaceuticals LLC, a clinical-stage oncology company, will merge with Boston-based Flex Pharma Inc. (Nasdaq: FLKS), according to a Jan. 4 press release.
The deal is expected to close in the first half of 2019, with Flex Pharma stockholders and current Salarius investors owning approximately 19.9 percent and 80.1 percent of the combined company, respectively. Flex Pharma stockholders also will have the right to receive warrants to purchase additional shares, which could…
